Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Oct 13 - Oct 18
For weight management, continuation criteria are product-specific: liraglutide 3mg (Saxenda) should be discontinued if less than 5% weight loss is achieved after 12 weeks at the maintenance dose
The 2025 Frontiers in Aging clinical review (Frontiers in Aging 2025) summarises the documented short-term adverse effects in adult populations: peripheral oedema and fluid retention are common at initiation, carpal tunnel syndrome occurs in a meaningful proportion of users, hyperglycaemia and insulin resistance can emerge because GH is physiologically counter-regulatory to insulin, and gynaecomastia has been reported, particularly at higher doses
Diakogiannaki E, Pais R, Tolhurst G, Parker HE, Horscroft J, Rauscher B, et al
Toxins (2018)
Most side effects are gastrointestinal and tend to diminish as the dose is gradually increased
For more information, visit or follow Ospaph on Facebook
